In vitro activity of telithromycin against macrolide-susceptible and macrolide-resistant pharyngeal isolates of group A streptococci in the United States

被引：5

作者：

Green, M

Allen, C

Bradley, J

Dashefsky, B

Gilsdorf, JR

Marcon, MJ

Schutze, GE

Smith, C

Walter, E

Martin, JM

Edwards, KA

Barbadora, KA

Rumbaugh, RM

Wald, ER

机构：

[1] Univ Pittsburgh, MPH Div Allergy Immunol & Infect Dis, Dept Pediat, Childrens Hosp Pittsburgh,Sch Med, Pittsburgh, PA 15213 USA

[2] Texas Childrens Hosp, Houston, TX 77030 USA

[3] Childrens Hosp San Diego, San Diego, CA USA

[4] UMDNJ, New Jersey Med Sch, Newark, NJ USA

[5] Univ Michigan, CS Mott Childrens Hosp, Ann Arbor, MI 48109 USA

[6] Childrens Hosp Columbus, Columbus, OH USA

[7] Arkansas Childrens Hosp, Little Rock, AR 72202 USA

[8] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[9] Duke Univ, Med Ctr, Durham, NC USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2005年 / 49卷 / 06期

关键词：

D O I：

10.1128/AAC.49.6.2487-2489.2005

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

In vitro susceptibility testing of 2,797 group A streptococcus (GAS) isolates demonstrated that telithromycin was fully active against all macrolide-susceptible strains and among 80 of 115 macrolide-resistant GAS expressing the M phenotype. Telithromycin resistance was identified in 2 of 45 strains expressing the inducible macrolide-lincosamide-streptogramin B phenotype and four of nine isolates expressing the constitutive macrolide-lincosamide-streptogramin B resistance phenotype.

引用

页码：2487 / 2489

页数：3

共 23 条

[1] Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA [J].

Barry, AL ;

Fuchs, PC ;

Brown, SD .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (01) :139-140

[2]

CHA S, 2001, KOREA J INFECT CHEMO, V7, P81

[3] IN-VITRO SUSCEPTIBILITY OF RECENT NORTH-AMERICAN GROUP-A STREPTOCOCCAL ISOLATES TO 11 ORAL ANTIBIOTICS [J].

COONAN, KM ;

KAPLAN, EL .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1994, 13 (07) :630-635

[4] Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993-1995 [J].

Cornaglia, G ;

Ligozzi, M ;

Mazzariol, A ;

Valentini, M ;

Orefici, G ;

Fontana, R .

EMERGING INFECTIOUS DISEASES, 1996, 2 (04) :339-342

[5] Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study [J].

Farrell, DJ ;

Morrissey, I ;

Bakker, S ;

Felmingham, D .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 :39-47

[6] Macholide resistance in group A Streptococcus [J].

Freeman, AF ;

Shulman, ST .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (12) :1158-1160

[7]

GERBER MA, 1995, PEDIATR CLIN N AM, V42, P539

[8] Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes:: SMART program 2001 data [J].

Hsueh, PR ;

Teng, LJ ;

Lee, CM ;

Huang, WK ;

Wu, TL ;

Wan, JH ;

Yang, D ;

Shyr, JM ;

Chuang, YC ;

Yan, JJ ;

Lu, JJ ;

Wu, JJ ;

Ko, WC ;

Chang, FY ;

Yang, YC ;

Lau, YJ ;

Liu, YC ;

Leu, HS ;

Liu, CY ;

Luh, KT .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) :2152-2157

[9] In vivo veritas:: In vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure [J].

Jacobs, MR .

CLINICAL INFECTIOUS DISEASES, 2002, 35 (05) :565-569

[10] In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species [J].

Jalava, J ;

Kataja, J ;

Seppälä, H ;

Huovinen, P .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :789-793

← 1 2 3 →